Outpatient teclistamab for multiple myeloma: a safety study
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or not responded to treatment, and you've had at least three different types of therapy before.
- You are 18 years or older.
- You have a caregiver who can stay with you around the clock for at least 27 days and help with tasks like taking your vital signs and giving medications.
- You have not had teclistamab or any other anti-BCMA therapy before.
- Your cancer has not spread to your brain or spinal cord, and you do not have large tumors outside of your bones.
- You are willing to receive treatment at a specific cancer center (Princess Margaret or Stronach Regional) and follow the study's safety rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This study looks closely at patients’ immune cells to understand why teclistamab helps in multiple myeloma. Your participation could help doctors better predict who benefits and how the treatment works.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.